IL110166A - Compositions containing 8-hydroxyquinoline in the treatment and preparation of psoriasis - Google Patents
Compositions containing 8-hydroxyquinoline in the treatment and preparation of psoriasisInfo
- Publication number
- IL110166A IL110166A IL11016694A IL11016694A IL110166A IL 110166 A IL110166 A IL 110166A IL 11016694 A IL11016694 A IL 11016694A IL 11016694 A IL11016694 A IL 11016694A IL 110166 A IL110166 A IL 110166A
- Authority
- IL
- Israel
- Prior art keywords
- hydroxyquinoline
- use according
- psoriasis
- solvent
- weight
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 26
- 238000002360 preparation method Methods 0.000 title description 6
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims abstract description 42
- 229960003540 oxyquinoline Drugs 0.000 claims abstract description 42
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000000699 topical effect Effects 0.000 claims abstract description 11
- 239000012071 phase Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- 239000012188 paraffin wax Substances 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 229960004311 betamethasone valerate Drugs 0.000 claims description 3
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940125379 topical corticosteroid Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000499 gel Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- -1 Hydroxypropyl Chemical group 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000003317 calciotropic effect Effects 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939313866A GB9313866D0 (en) | 1993-07-05 | 1993-07-05 | Compositions for the treatment of inflammatory proliferative skin disease and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL110166A0 IL110166A0 (en) | 1994-10-07 |
| IL110166A true IL110166A (en) | 1998-08-16 |
Family
ID=10738317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11016694A IL110166A (en) | 1993-07-05 | 1994-06-29 | Compositions containing 8-hydroxyquinoline in the treatment and preparation of psoriasis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5817675A (de) |
| EP (1) | EP0634170B1 (de) |
| AT (1) | ATE150644T1 (de) |
| AU (1) | AU674411B2 (de) |
| CA (1) | CA2127218A1 (de) |
| DE (1) | DE69402259T2 (de) |
| ES (1) | ES2102777T3 (de) |
| GB (1) | GB9313866D0 (de) |
| IL (1) | IL110166A (de) |
| NZ (1) | NZ260875A (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846919B2 (en) * | 1998-02-10 | 2010-12-07 | Dermex Pharmaceuticals, Llc | Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
| US20040248874A1 (en) * | 2001-10-12 | 2004-12-09 | Jemmett Alan Edwin | Anti-microbial composition comprising a metal ion chelating agent |
| WO2006021008A2 (en) * | 2004-08-20 | 2006-02-23 | Lind Stuart E | Ionophores as cancer chemotherapeutic agents |
| WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
| US20140179645A1 (en) * | 2012-12-21 | 2014-06-26 | The Pisces Group Llc | Antimicrobial compositions |
| US10155936B2 (en) | 2014-12-05 | 2018-12-18 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
| US10308617B2 (en) | 2016-06-03 | 2019-06-04 | An2H Discovery Limited | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| US10889553B2 (en) | 2017-12-01 | 2021-01-12 | Nysnobio Ireland Dac | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| JP2022525221A (ja) | 2019-03-14 | 2022-05-11 | クレシタ セラピューティクス インコーポレイテッド | 洗い流し組成物および活性剤を送達するためのそれらの使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB643860A (en) * | 1946-04-15 | 1950-09-27 | Ethan Allan Brown | Improvements in or relating to liquid antiseptics |
| GB981144A (en) * | 1963-03-25 | 1965-01-20 | Licencia Talalmanyokat | A pharmaceutical formulation for the treatment of dermatophytoses |
| US4038388A (en) * | 1974-03-29 | 1977-07-26 | Paterson Zochonis & Company Limited | Antimicrobial compositions |
| US3944668A (en) * | 1974-03-29 | 1976-03-16 | Paterson Zochonis & Company, Limited | Antimicrobial compositions |
| GB2076286B (en) * | 1980-05-23 | 1984-06-13 | Quinoderm Ltd | Dermatological hydrogen peroxide compositions |
| GB2076285B (en) * | 1980-05-23 | 1984-04-04 | Quinoderm Ltd | Dermatological compositions |
| IE60024B1 (en) * | 1987-02-03 | 1994-05-18 | Stiefel Laboratories Ltd | Microemulsions |
-
1993
- 1993-07-05 GB GB939313866A patent/GB9313866D0/en active Pending
-
1994
- 1994-06-23 DE DE69402259T patent/DE69402259T2/de not_active Expired - Fee Related
- 1994-06-23 ES ES94304561T patent/ES2102777T3/es not_active Expired - Lifetime
- 1994-06-23 EP EP94304561A patent/EP0634170B1/de not_active Expired - Lifetime
- 1994-06-23 AT AT94304561T patent/ATE150644T1/de not_active IP Right Cessation
- 1994-06-29 NZ NZ260875A patent/NZ260875A/en unknown
- 1994-06-29 IL IL11016694A patent/IL110166A/en not_active IP Right Cessation
- 1994-06-30 AU AU66089/94A patent/AU674411B2/en not_active Ceased
- 1994-06-30 CA CA002127218A patent/CA2127218A1/en not_active Abandoned
-
1997
- 1997-05-27 US US08/863,396 patent/US5817675A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5817675A (en) | 1998-10-06 |
| DE69402259D1 (de) | 1997-04-30 |
| AU674411B2 (en) | 1996-12-19 |
| GB9313866D0 (en) | 1993-08-18 |
| ES2102777T3 (es) | 1997-08-01 |
| DE69402259T2 (de) | 1997-07-24 |
| AU6608994A (en) | 1995-01-12 |
| IL110166A0 (en) | 1994-10-07 |
| EP0634170B1 (de) | 1997-03-26 |
| NZ260875A (en) | 1997-07-27 |
| EP0634170A1 (de) | 1995-01-18 |
| ATE150644T1 (de) | 1997-04-15 |
| CA2127218A1 (en) | 1995-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5990100A (en) | Composition and method for treatment of psoriasis | |
| US5422361A (en) | Stable cream and lotion bases for lipophilic drug compositions | |
| EP0481007B1 (de) | VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL | |
| US3749773A (en) | Gelled steroid ointment | |
| CA2301009C (en) | Skin care compositions and use | |
| CZ390099A3 (cs) | Lotion na bázi emulzí aktivního vitamínu D3 | |
| EP0471872A1 (de) | Antimykotische Gelpräparate | |
| SA92130087B1 (ar) | تركيب صيدلي محتوي على مركب اللايل أمين | |
| JP2003533491A (ja) | 薬学的及び／又は美容的組成物 | |
| EP0355152A1 (de) | Topische metronidazol-formulationen und deren verwendung als arzneimittel. | |
| JPH032118A (ja) | ビタミンａ酸の局所塗布用保湿性賦形剤 | |
| CA2148109C (en) | 1.alpha., 24-(oh)2-v.d.3 emulsion composition | |
| JP7268132B2 (ja) | 局所用組成物 | |
| JPH0148885B2 (de) | ||
| US5817675A (en) | Compositions for the treatment of psoriasis and their use | |
| JPS58225009A (ja) | コルチコステロイド外用製剤 | |
| JPH0463852B2 (de) | ||
| JPH0676328B2 (ja) | ステロイドクリ−ム製剤 | |
| HK1052873A1 (en) | Two-phase hydrogel for application in drops at the eye | |
| GB2279567A (en) | Topical 8-hydroxyquinoline compositions | |
| JP5125122B2 (ja) | アダパレン含有外用剤組成物 | |
| FR2588474A1 (fr) | Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste | |
| JP5233149B2 (ja) | アダパレン含有外用剤組成物 | |
| JP5109383B2 (ja) | アダパレン含有外用剤組成物 | |
| FI118953B (fi) | Ulkoisesti käytettävä, nimesulidia käsittävä tulehdusta torjuva aine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| RH | Patent void |